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Health care is always a top priority in this country and often the
topic of discussion and debate.
In 2004, Medicare spent $300
billion on health care costs, making it the largest purchaser of
healthcare in the nation.1
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In an effort to improve the quality of health care and decrease
costs, the Department of Health
and Human Services (DHHS)
and the Centers for Medicare
and Medicaid Services (CMS)
have joined to create a program
called the Quality Initiative. The
purpose of the Initiative is to encourage health care providers to
enhance the quality of care by
providing financial incentive and
to empower consumers with
quality of care information to
make more informed decisions
about their health care.
This program was launched in
2002 and began with nursing
homes. The Quality Initiative
for hospitals and home health
care agencies was nationally
launched in 2003. Finally, the
Initiative was expanded in
2004 to include kidney dialysis
facilities.

The Initiative distributes data on
hospital performance with the
goal of creating incentives for
hospitals to improve the care provided to patients. With hospitals
improving their performance, it is
expected that costs for Medicare
would decrease in return.
In order to encourage hospitals to
submit the quality data, a law was
incorporated into the Medicare
Prescription Drug, Improvement,
and Modernization Act of 2003
stating that if data for the 10 quality measures (“starter set”) were
not submitted, the hospital would
receive a reduction of 2 percentage points in their Medicare Annual Payment Update for fiscal
year 2007. Conversely, the project
will provide bonuses to hospitals
that excel in their achievement of
quality measures. Hospitals in the
top 10% for performance will get
a 2% bonus on their Medicare
payments, while those in the
second 10% will receive a 1%
bonus.1
The Hospital Quality Initiative is
divided into the following 4 clinical areas: acute myocardial infarction (AMI), heart failure (HF),
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community-acquired pneumonia,
and surgical care improvement/
surgical infection prevention.1,2
There are a total of 21 specific
quality measures that hospitals
should strive to achieve within
these clinical areas. Hospitals are
required to submit data on the 10
“starter set” measures and submission of data on the expanded set of
quality measures (21 measures)
began with discharges that occur
in the third calendar quarter of
2006 (July through September).
Starting this month there will be a
5-article series devoted to the Initiative. The purpose of the articles
is to inform health care providers
about the Initiative, explain how
the data are reported, and report
our current compliance. This
month we will be focusing on the
AMI measures.
Every year there are about
865,000 acute myocardial infarctions in the United States, where

20% of men and 30% of women
will die within 1 year of an initial recognized event.3 AMI is
among the leading causes of hospital admission for Medicare
beneficiaries age 65 years and
older.4
Table 1 lists the current measures for AMI. These outcomes
coincide with the recommendations published by the American
College of Cardiology/American
Heart Association for clinical
performance measures for adults
with AMI.3 Scientific evidence
indicates that the measures represent the best practice for the
treatment of AMI. For more detailed information regarding the
hospital measures visit the Hospital Quality Initiative Web site
(http://www.cms.hhs.gov/
HospitalQualityInits/downloads/
HospitalOverviewOfSpecs200512.pdf ).

Starting in April 2007, the following measures will be added
to the AMI Initiative: median

time to fibrinolysis, median time
to PCI, LDL cholesterol assessment, and lipid lowering therapy
at discharge. In June 2007, CMS
will require risk-adjusted, 30-day
mortality rates for all Medicare
patients with principal hospital
discharge diagnosis of AMI or HF
from all acute care and critical
access hospitals in the nation.
Once submitted, the data are accessible online to consumers
through the DHHS Web site
Hospital
Compare
( www.hospitalcompare.hhs.gov ).
The rates of compliance with each
measure are available for MUSC,
other local hospitals, as well state
and national averages.
The Outcomes and Quality Management division collects data on
all patients who were discharged
with a primary diagnosis of AMI.
The data regarding performance
with the specific measures are en-

Table 1. AMI Quality Measures
Measure
Aspirin at arrival
Aspirin at discharge
ACEI or ARB for LVSD
Beta-blocker at arrival
Beta-blocker at discharge
Fibrinolytic therapy within
30 minutes of hospital arrival
PCI within 120 minutes of
hospital arrival
Smoking cessation advice/
counseling

Description
AMI patients without contraindications to aspirin therapy who received aspirin
within 24 hours before or after hospital arrival.
AMI patients without contraindications to aspirin therapy who are prescribed aspirin
at hospital discharge.
AMI patients with left ventricular systolic dysfunction (LVSD) and without both angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker
(ARB) contraindications who are prescribed an ACEI or ARB at hospital discharge.
AMI patients without contraindications to beta-blocker therapy who received a betablocker within 24 hours after hospital arrival.
AMI patients without contraindications to beta-blocker therapy who are prescribed a
beta-blocker at hospital discharge.
AMI patients receiving fibrinolytic therapy during the hospital stay and having a time
from hospital arrival to fibrinolysis of 30 minutes or less.
[Part of the expanded set of quality measures]
AMI patients receiving percutaneous coronary intervention (PCI) during the hospital
stay with a time from hospital arrival to PCI of 120 minutes or less.
[Part of the expanded set of quality measures]
AMI patients with a history of smoking cigarettes (defined as smoked at any time
during the past 12 months) who are given smoking cessation advice or counseling
during hospital stay. [Part of the expanded set of quality measures]
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Table 2. 2006 Compliance Rate with Quality Measures
Jan to Jun
2006

Jul to Sept
2006

National
Average
Through
March 2006

Aspirin at arrival

100%

100%

92%

Aspirin at discharge

99%

100%

89%

ACEI or ARB for LVSD

85%

90%

81%

Beta blocker at arrival

100%

100%

86%

Beta blocker at discharge

98%

100%

89%

Fibrinolytic therapy
within 30 minutes

NA*

NA*

30%

PCI within 120 minutes

59%

50%

67%

Smoking cessation advice
or counseling

97%

100%

85%

MUSC Rate of Compliance
Quality Measure

* No patients meet the criteria for inclusion for this measure—patients are taken directly to PCI

tered into a database and submitted to CMS. Currently, data are
available for discharges during the
months of January through June
2006 and July through September
2006 (Table 2).
To remain compliant with the
measures, it is important that each
measure is properly documented
in the patient’s medical record.
For AMI, the adult cardiac admission preprinted order form
(www.musc.edu/cce/ORDFRMS/pdf/
cardiacadmit.pdf) contains check
areas for prescribing the specified
medications (ie, aspirin, beta
blocker, ACEI or ARB) on admission. For discharges, the cardiovascular discharge form
(www.musc.edu/cce/ORDFRMS/pdf/
cardiovascdc.pdf) is available on
the clinical order forms web page
under cardiology. The discharge
medication section specifically
lists aspirin, beta blocker and
ACEI or ARB to provide an area
for documentation. Most of the
failures for the medication measures may be due to poor documen-

tation of the reason for not prescribing.
If there is any contraindication
for therapy, it must be documented in the patient’s medical
record for both admission and
discharge. This can be docu-

The

mented on the admission form by
marking “not prescribed because”
and listing the reason on the discharge form. For smoking cessation advise/counseling, the following preprinted order forms have
designated places to document
that this was provided:
▪ Adult Cardiac Admission
▪ Cardiovascular Discharge
▪ Inpatient History and Physical
form (page 6 of the form)
▪ Discharge Orders - general
(page 2 of the form)
▪ Emergency Department Cardiac.
The CMS quality measures encourage hospitals to improve the
quality of patient care. The individual measures for the 4 clinical
areas offer hospitals specific goals
that can be used to improve patient care in those disease states.
As part of the MUSC Excellence
campaign, the organization has
established a goal of at least 95%
compliance with all CMS quality

MED•U•WAY
To Care For Patients
*** An MUSC Lecture Series***

The next MED•U•WAY
Program will focus on attention
deficit disorder (ADD) and
attention deficit/hyperactivity
disorder (ADHD). The program
will be held on Thursday, April
19, 2007, at 12:00 PM, in 2 West
Amphitheater.
The featured speakers will be
Mark Wagner, MD, Assistant
Professor, Department of
Psychiatry and Behaviroal
Sciences, Shannon Drayton,

PharmD, BCPP, Assistant
Professor, College of Pharmacy
and Mary Lou Shoemaker, MSW,
LISW-CP, Assistant Professor,
Department of Psychiatry and
Behaviroal Sciences.
Attendees will receive 1 credit
hour of continuing education, and
lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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measures; therefore, is it critical
that every health care professional
is aware of the CMS Initiative,
how the organization is performing, and where we need to focus
our efforts. In 5 of the 8 AMI
measures, the organizational goal
of at least 95% has been reached.
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Additionally, MUSC exceeds the
national average in all measures
except for primary PCI. However, there is still a need for improvement in prescribing ACEI
or ARB at discharge and primary
PCI within 90 minutes. Therefore, our efforts should focus on

proper documentation.
All health care providers have a
role in improving our performance
in these quality measures. This
will translate into improved patient outcomes.
References available upon request

FORMULARY UPDATE
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below, which were
effective on March 15, 2007.

propriate dosing due to the formulary changes. Please visit the
Formulary and Drug Information
Resources Web page for more
details.

Added with Restriction:
Etonogestrel (Implanon®)
Subdermal implant
Prescribing is restricted to patients
in the outpatient setting who receive prior authorization. Additionally, any physician that intends to use the device must undergo clinical training prior to
procurement.

www.formularyproductions.com/musc

Ertapenem (Invanz®)
1-gram vial
Prescribing is restricted to the infectious diseases and surgery services for the following indications:
treatment
of
intraabdominal infections; treatment of
gynecologic infections; and treatment of complicated skin and skin
structure infections. The ertapenem order form must be used for
prescribing. The formulary effective will be set when the preprinted order form is approved by
the forms committee.
Automatic Therapeutic Substitution (ATS) Protocol:
Effective March 15, 2007
An ATS for meropenem has been
developed by the Anti-infective
Subcommittee to assist with ap-

Restriction Removed:
Effective March 15, 2007
Meropenem (Merrem®)
The formulary restriction was
removed with the deletion of
imipenem/cilastatin.
Restriction Added:
Effective March 15, 2007
Levonorgestrel intrauterine device (Mirena®)
Prescribing is restricted to patients in the outpatient setting
who receive prior authorization.
No Change in Restriction
Tigecycline (Tygacil®)
A request to remove the current
restriction for tigecycline (ie,
attending physicians and fellows
on the Infectious Diseases service [Formal Consult Required])
was denied. The current restriction will remain in place.
Line extensions:
Triamcinolone hexacetonide
(Aristospan®)
5 mg/mL (5-mL vial)

BCG live vaccine (TICE®)
50-mg vial
Glycerin 50% solution
Extemporaneous solution
Deletions:
Imipenem/cilastatin (Primaxin®)
250-mg/250-mg and 500mg/500-mg powder for injection
BCG live vaccine (Theracys®)
81-mg vial
Glycerin 50% (Osmoglyn®)
50% solution
Dorzolamide (Trusopt®)
10-mL bottle
Orders Approved:
Children’s Emergency Services
Pain Standing Orders
Standing orders were developed in
an effort to increase pain management for children receiving nonemergent painful procedures. This
order form will allow nursing staff
to have evidence-based orders to
increase analgesia and decrease
anxiety for common painful procedures.
Standing Orders for the Medical
Emergency Team (MET)
Standing orders were developed
for nurses on the Medical Emergency Team. Any other orders
will be written by the physician.

